Second Line Bismuth Containing Quadruple Therapy With Supplementary Probiotic
H.Pylori Gastrointestinal Disease
About this trial
This is an interventional supportive care trial for H.Pylori Gastrointestinal Disease focused on measuring supplementary pylori, Bismuth quadruple therapy, H. pylori eradication
Eligibility Criteria
Inclusion Criteria:
Patients older than 20 years-old underwent documented non-Bismuth containing 1st line H. pylori eradication with failure defined by positive 13C-Urea Breath Test (13C-UBT) at least 6 weeks after completion of therapy is eligible to the study.
Exclusion Criteria:
- History of gastrectomy, surgery in the small intestine or colon
- History of gastric malignancy, including adenocarcinoma or lymphoma
- Allergic history, history of severe adverse effects or contraindication to antibiotics (Tetracycline, Metronidazole ), proton pump inhibitor, or probiotics
- Pregnant or lactating women
- Severe concurrent chronic or acute disease (e.g. renal failure, liver cirrhosis, or active malignancy)
- Concomitant use of clopidogrel or warfarin
- Recent (<4 weeks) use of antibiotics, or recent (<4 weeks) probiotic use duration >2 weeks
- Not able to give consent on blinding or randomizatio
- Not able to give consent by his or herself
Sites / Locations
- National Taiwan University Hospital Yunlin BranchRecruiting
- Kaohsiung Medical University Chung-Ho Memorial Hospital
- National Taiwan University HospitalRecruiting
- National Taiwan University Cancer CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Probiotics packets
Placebo packets
Probiotics contains 450 billion colony-forming units per packet. The compositions are maltose, lactic acid bacteria and bifidobacteria blend, cornstarch, silicon dioxide.
The compositions are maltodextrin, silicon dioxide, sucralose